Neel Parekh

Research Associate @ Low Institute for Therapeutics

Role: Bioanalytical Assay Development Co-op - Preclinical Pharmacology & Toxicology at Verve Therapeutics
Location: Boston, MA, US
LinkedIn followers: 500 followers

ScienceView LinkedIn profile

Experience

Bioanalytical Assay Development Co-op - Preclinical Pharmacology & Toxicology
Verve Therapeutics
Present

Education

SVKM's Narsee Monjee Institute of Management Studies (NMIMS)
Bachelor of Science, Pharmaceutical Sciences
2019 — 2023
Northeastern University
Master of Science, Pharmaceutical Sciences
2023 — 2025

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@vervetx.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Verve Therapeutics

Biotechnology Research · 160 employees · Founded 2018 · Boston, Massachusetts, United States

Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company\'s lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis.

vervetx.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Bioanalytical Assay Development Co-op - Preclinical Pharmacology & Toxicology

Education

SVKM's Narsee Monjee Institute of Management Studies (NMIMS)

Northeastern University

Find verified contacts for anyone on LinkedIn